Boice J D, Blettner M, Kleinerman R A, Engholm G, Stovall M, Lisco H, Austin D F, Bosch A, Harlan L, Krementz E T, Latouret H B, Merril J A, Petters L J, Schulz M D, Wactawski J, Storm H H, Björkholm E, Pettersson F, Bell C M, Coleman M P, Fraser P, Neal F E, Prior P, Choi N W, Hislop T G, Koch M, Kreiger N, Robb D, Robson D, Thomson D H, Lochmüller H, von Fournier D, Frischkorn R, Kjørstad K E, Rimpela A, Pejovic M H, Kirn V P, Stankusova H, Pisani P, Sigurdsson K, Hutchison G B, MacMahon B
Radiation Epidemiology Branch, National Cancer Institute, Bethesda, MD 20892.
Int J Cancer. 1989 Jul 15;44(1):7-16. doi: 10.1002/ijc.2910440103.
The relationship between breast cancer and radiation treatment for cervical cancer was evaluated in an international study of 953 women who subsequently developed breast cancer and 1,806 matched controls. Radiation doses to the breast (average 0.31 Gy) and ovaries (average 32 Gy) were reconstructed for exposed subjects on the basis of their original radiotherapy records. Overall, 88% of the breast cancer cases and 89% of the controls received radiation treatment [relative risk (RR) = 0.88; 95% confidence interval (CI) = 0.7-1.2]. Among women with intact ovaries (561 cases, 1,037 controls), radiotherapy was linked to a significant 35% reduction in breast cancer risk, attributable in all likelihood to the cessation of ovarian function. Ovarian doses of 6 Gy were sufficient to reduce breast cancer risk but larger doses did not reduce risk further. This saturation-type response is probably due to the killing of a critical number of ovarian cells. Cervical cancer patients without ovaries (145 cases, 284 controls) were analyzed separately because such women are at especially low natural risk for breast cancer development. In theory, any effect of low-dose breast exposure, received incidentally during treatment for cervical cancer, should be more readily detectable. Among women without ovaries, there was a slight increase in breast cancer risk (RR = 1.07; 95% CI = 0.6-2.0), and a suggestion of a dose response with the RR being 1.0, 0.7, 1.5 and 3.1 for breast doses of 0, 0.01-0.24, 0.25-0.49 and 0.50+ Gy, respectively. However, this trend of increasing RR was not statistically significant. If low-dose radiation increases the risk of breast cancer among women over age 40 years, it appears that the risk is much lower than would be predicted from studies of younger women exposed to higher doses.
在一项针对953名后来罹患乳腺癌的女性和1806名匹配对照的国际研究中,评估了乳腺癌与宫颈癌放射治疗之间的关系。根据暴露受试者原来的放疗记录,重建了其乳房(平均0.31 Gy)和卵巢(平均32 Gy)所接受的辐射剂量。总体而言,88%的乳腺癌病例和89%的对照接受过放射治疗[相对危险度(RR)=0.88;95%置信区间(CI)=0.7 - 1.2]。在卵巢功能完好的女性中(561例病例,1037名对照),放射治疗与乳腺癌风险显著降低35%相关,这很可能归因于卵巢功能的停止。6 Gy的卵巢剂量足以降低乳腺癌风险,但更大剂量并未进一步降低风险。这种饱和型反应可能是由于关键数量的卵巢细胞被杀死。对没有卵巢的宫颈癌患者(145例病例,284名对照)进行了单独分析,因为这类女性患乳腺癌的自然风险特别低。理论上,在宫颈癌治疗期间偶然接受的低剂量乳房照射的任何影响应该更容易被检测到。在没有卵巢的女性中,乳腺癌风险略有增加(RR = 1.07;95% CI = 0.6 - 2.0),并且有剂量反应的迹象,乳房剂量为0、0.01 - 0.24、0.25 - 0.49和0.50 + Gy时,RR分别为1.0、0.7、1.5和3.1。然而,这种RR增加的趋势在统计学上并不显著。如果低剂量辐射会增加40岁以上女性患乳腺癌的风险,那么这种风险似乎比在接受高剂量辐射的年轻女性研究中预测的要低得多。